Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Alimta as First Line Chemotherapy for Advanced or Metastatic Breast Cancer

NCT00106002 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00106002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00106002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Alimta as First Line Chemotherapy for Advanced or Metastatic Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2005
Completion date
December 31, 2007
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms, male, carcinoma, ductal